For more information please contact:
Managing Director &
Head of Healthcare
Equity Capital Markets
Head of Equity
Senior Vice President
Senior Vice President
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, has closed an underwritten public offering of 5,400,000 shares of common stock. The shares were sold at the public offering price of $14.00 per share, resulting in the gross proceeds to Syros Pharmaceuticals of approximately $75.6 million. Syros Pharmaceuticals intends to use the proceeds of the offering to fund the development of Syros’ ongoing clinical and preclinical programs, and for working capital and other general corporate purposes. In addition, Syros has also granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock.
Roth Capital Partners acted as co-manager for the offering.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, please visit
(Sour(Source: Company Press Release | 01.19.21)
About Roth Capital Partners
Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and
their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading,
market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and
maintains offices throughout the U.S. For more information on ROTH, please visit
Date of Announcement: 01.26.21
The material, information and facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC
("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any
companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or
estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be
reproduced in any form without the express written permission of Roth. Copyright 2021.